You Create the Future of
Regenerative Medicine.

We Make the Road
There Smoother.

Transitioning cell and gene therapies from lab to patient is intricate, involving many requirements and standards like GMP. CCRM Nordic is a not for profit organization supported by the Swedish Government offering the expertise and facilities needed to navigate these challenges.

Development Expertise

We engage in many parts of building a business, from CMC, analytical and process development to business support helping companies with critical aspects such as de-risking, technology and therapy development and IP.

GMP Facilities and Clinical Manufacturing

We are building approximately 3000 sqm lab facilities covering analytical and process development and GMP manufacturing for clinical studies.

Industry Network & Global Reach

As a CCRM hub we are part of a global network. We work with the industry in a long-term manner to support ATMP development from all angles, including lowering COGS and improving regulatory standards.

“Advancing cell and gene therapies requires collaborations that make technologies and solutions accessible to early-stage researchers. Creating an infrastructure that provides access to scalable and flexible solutions will enable research to progress at greater speed. Cytiva is proud to work with CCRM to help accelerate the development of next generation therapeutics.”

Catarina Flyborg

Senior Advisor, CCRM Board Director

What is CCRM Nordic?

CCRM Nordic is a not for profit organization with the purpose to address bottlenecks in the translation and commercialization of advanced therapy medicinal products (ATMPs). We are based in Gothenburg Sweden, supporting innovators in the Nordics and Europe.

Read more

Backed and Trusted by Both Private and Public Sector

CCRM Nordic is a public-private partnership, backed by well renowned industry leaders, SMEs and the Swedish Innovation Agency Vinnova.

Read more

News and Events

26 June 2024

CCRM Nordic Welcomes Frank Waldron-Lynch to the Board of Directors

Read more
19 June 2024

CCRM International Regenerative Medicine SuperPitch VII

Read more
8 May 2024

New Modality Support is implemented – for commercialization of research from OligoNova and CCRM Nordic

Read more
25 April 2024

CCRM Nordic Announces Formation of New Scientific Advisory Board to Propel Regenerative Medicine Innovations

Read more
25 January 2024

CCRM Nordic and GoCo announces the construction of GoCo Active Lab

Read more
11 January 2024

CCRM Nordic appoints Dr. Anna Falk as Chief Scientific Officer

Read more
24 May 2023

Vinnova supports the formation of a Nordic CCRM hub

Read more